| Identification | Back Directory | [Name]
methyl 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxy | [CAS]
1372540-24-3 | [Synonyms]
GSK2636771 methyl
methyl 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxy
methyl 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate
Methyl 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate
1H-Benzimidazole-4-carboxylic acid, 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-, methyl ester | [Molecular Formula]
C23H24F3N3O3 | [MDL Number]
MFCD30607354 | [MOL File]
1372540-24-3.mol | [Molecular Weight]
447.45 |
| Hazard Information | Back Directory | [Uses]
GSK2636771 methyl (compound II) is an inhibitor of PI3Kβ. GSK2636771 methyl can be used in the research of cancer combined with VT-464 (HY-15996)[1]. | [References]
[1] Joel GRESHOCK, et al. Combination drug therapy. WO2015042027A1. 2014 |
|
|